High-throughput screening for human collagenase 1 inhibitors

Acta Pharmacologica Sinica

Volumn 21, Issue 11, 2000, Pages 1021-1026

  Ye, Q Z ^a   Nan, F J ^a   Hu, L Y ^a   Qian, Z ^a   Qian, J ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Drug screening; High throughput screening; Matrix metalloproteinase

Indexed keywords

COLLAGENASE INHIBITOR; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS;

COLLAGENASES; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; INHIBITORY CONCENTRATION 50; RECOMBINANT PROTEINS;

EID: 0033710359     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Cloning and characterization of human tumor cell interstitial collagenase
2. Matrix metalloproteinases and their inhibitors in connective tissue remodeling
3. Design and therapeutic application of matrix metalloproteinase inhibitors
4. Human fibroblast stromelysin catalytic domain: Expression, purification, and characterization of a C-terminally truncated form
5. Reconstructed 19 kDa catalytic domain of gelatinase A is an active proteinase
6. Purification and characterization of the human stromelysin catalytic domain expressed in Escherichia coli
7. A recombinant human stromelysin catalytic domain identifying trytophan derivatives as human stromelysin inhibitors
8. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain
9. The recombinant catalytic domain of human neutrophil collagenase lacks type I collagen substrate specificity
10. Spectrophotometric assay for vertebrate collagenase
11. Tissue sulfhydryl groups
12. Characterization of the Phe-81 and Val-82 human fibroblast collagenase catalytic domain purified from Escherichia coli
13. Inhibition of Human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids
14. Challenges and opportunities in high throughput screening: Implications for new technologies